1
|
Singh A, Singh K, Kaur K, Singh A, Sharma A, Kaur K, Kaur J, Kaur G, Kaur U, Kaur H, Singh P, Bedi PMS. Coumarin as an Elite Scaffold in Anti-Breast Cancer Drug Development: Design Strategies, Mechanistic Insights, and Structure-Activity Relationships. Biomedicines 2024; 12:1192. [PMID: 38927399 PMCID: PMC11200728 DOI: 10.3390/biomedicines12061192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2024] [Revised: 05/24/2024] [Accepted: 05/25/2024] [Indexed: 06/28/2024] Open
Abstract
Breast cancer is the most common cancer among women. Currently, it poses a significant threat to the healthcare system due to the emerging resistance and toxicity of available drug candidates in clinical practice, thus generating an urgent need for the development of new potent and safer anti-breast cancer drug candidates. Coumarin (chromone-2-one) is an elite ring system widely distributed among natural products and possesses a broad range of pharmacological properties. The unique distribution and pharmacological efficacy of coumarins attract natural product hunters, resulting in the identification of numerous natural coumarins from different natural sources in the last three decades, especially those with anti-breast cancer properties. Inspired by this, numerous synthetic derivatives based on coumarins have been developed by medicinal chemists all around the globe, showing promising anti-breast cancer efficacy. This review is primarily focused on the development of coumarin-inspired anti-breast cancer agents in the last three decades, especially highlighting design strategies, mechanistic insights, and their structure-activity relationship. Natural coumarins having anti-breast cancer efficacy are also briefly highlighted. This review will act as a guideline for researchers and medicinal chemists in designing optimum coumarin-based potent and safer anti-breast cancer agents.
Collapse
Affiliation(s)
- Atamjit Singh
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | - Karanvir Singh
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | | | - Amandeep Singh
- Department of Pharmacology, Penn State Cancer Institute, CH72, Penn State College of Medicine, Penn State Milton S. Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA;
| | - Aman Sharma
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | - Kirandeep Kaur
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | - Jaskirat Kaur
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | - Gurleen Kaur
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
| | - Uttam Kaur
- University School of Business Management, Chandigarh University, Gharuan 140413, Mohali, India;
| | - Harsimran Kaur
- Department of Pharmaceutical Chemistry, Khalsa College of Pharmacy, Amritsar 143005, Punjab, India; (H.K.); (P.S.)
| | - Prabhsimran Singh
- Department of Pharmaceutical Chemistry, Khalsa College of Pharmacy, Amritsar 143005, Punjab, India; (H.K.); (P.S.)
| | - Preet Mohinder Singh Bedi
- Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, Punjab, India; (K.S.); (A.S.); (K.K.); (J.K.); (G.K.)
- Drug and Pollution Testing Laboratory, Guru Nanak Dev University, Amritsar 143005, Punjab, India
| |
Collapse
|
2
|
Amatya E, Subramanian C, Cohen MS, Blagg BSJ. Development of Hsp90 C-terminal inhibitors with noviomimetics that manifest anti-proliferative activities. RSC Med Chem 2024; 15:888-894. [PMID: 38516588 PMCID: PMC10953479 DOI: 10.1039/d3md00529a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 01/12/2024] [Indexed: 03/23/2024] Open
Abstract
Inhibition of the Hsp90 C-terminal domain offers a promising opportunity to treat numerous diseases/indications. Furthermore, the development of Hsp90 C-terminal inhibitors (CTIs) is advantageous over N-terminal inhibitors because it avoids the detriments associated with induction of the heat shock response (HSR). However, the lack of co-crystal structures of small molecules bound to the C-terminus have hindered their development. Therefore, structure-activity relationship (SAR) studies have been pursued to optimize such inhibitors. Noviose sugar surrogates, also known as noviomimetics have been prepared to investigate the size and nature of the C-terminal domain binding pocket. Herein, we report the synthesis and anti-proliferative activity manifested by this new series of Hsp90 C-terminal inhibitors.
Collapse
Affiliation(s)
- Eva Amatya
- Department of Chemistry and Biochemistry, Warren Center for Drug Discovery, University of Notre Dame Notre Dame Indiana 46556 USA
| | - Chitra Subramanian
- Cancer Center at Illinois, University of Illinois Urbana-Champaign Urbana Illinois 61801 USA
| | - Mark S Cohen
- Cancer Center at Illinois, University of Illinois Urbana-Champaign Urbana Illinois 61801 USA
| | - Brian S J Blagg
- Department of Chemistry and Biochemistry, Warren Center for Drug Discovery, University of Notre Dame Notre Dame Indiana 46556 USA
| |
Collapse
|
3
|
Abstract
HSP90 (heat shock protein 90) is an ATP-dependent molecular chaperone involved in a proper folding and maturation of hundreds of proteins. HSP90 is abundantly expressed in cancer, including melanoma. HSP90 client proteins are the key oncoproteins of several signaling pathways controlling melanoma development, progression and response to therapy. A number of natural and synthetic compounds of different chemical structures and binding sites within HSP90 have been identified as selective HSP90 inhibitors. The majority of HSP90-targeting agents affect N-terminal ATPase activity of HSP90. In contrast to N-terminal inhibitors, agents interacting with the middle and C-terminal domains of HSP90 do not induce HSP70-dependent cytoprotective response. Several inhibitors of HSP90 were tested against melanoma in pre-clinical studies and clinical trials, providing evidence that these agents can be considered either as single or complementary therapeutic strategy. This review summarizes current knowledge on the role of HSP90 protein in cancer with focus on melanoma, and provides an overview of structurally different HSP90 inhibitors that are considered as potential therapeutics for melanoma treatment.
Collapse
Affiliation(s)
| | - Mariusz L Hartman
- Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215, Lodz, Poland
| | - Malgorzata Czyz
- Department of Molecular Biology of Cancer, Medical University of Lodz, 6/8 Mazowiecka Street, 92-215, Lodz, Poland.
| |
Collapse
|
4
|
Mbaba M, de la Mare JA, Sterrenberg JN, Kajewole D, Maharaj S, Edkins AL, Isaacs M, Hoppe HC, Khanye SD. Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition. J Biol Inorg Chem 2018; 24:139-149. [PMID: 30542925 DOI: 10.1007/s00775-018-1634-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 12/04/2018] [Indexed: 12/22/2022]
Abstract
A series of tailored novobiocin-ferrocene conjugates was prepared in moderate yields and investigated for in vitro anticancer and antiplasmodial activity against the MDA-MB-231 breast cancer line and Plasmodium falciparum 3D7 strain, respectively. While the target compounds displayed moderate anticancer activity against the breast cancer cell line with IC50 values in the mid-micromolar range, compounds 10a-c displayed promising antiplasmodial activity as low as 0.889 µM. Furthermore, the most promising compounds were tested for inhibitory effects against a postulated target, heat shock protein 90 (Hsp90). A selection of tailored novobiocin derivatives bearing the organometallic ferrocene unit were synthesized and characterized by common spectroscopic techniques. The target compounds were investigated for in vitro anticancer and antimalarial activity against the MDA-MB-231 breast cancer cell line and Plasmodium falciparum 3D7 strain, respectively.
Collapse
Affiliation(s)
- Mziyanda Mbaba
- Department of Chemistry, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.
| | - Jo-Anne de la Mare
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa.,Centre for Chemico- and Biomedical Research, Rhodes University, Grahamstown, 6140, South Africa
| | - Jason N Sterrenberg
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa
| | - Deborah Kajewole
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa
| | - Shantal Maharaj
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa
| | - Adrienne L Edkins
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa.,Centre for Chemico- and Biomedical Research, Rhodes University, Grahamstown, 6140, South Africa
| | - Michelle Isaacs
- Centre for Chemico- and Biomedical Research, Rhodes University, Grahamstown, 6140, South Africa
| | - Heinrich C Hoppe
- Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa.,Biomedical Biotechnology Research Unit (BioBRU), Rhodes University, Grahamstown, 6140, South Africa.,Centre for Chemico- and Biomedical Research, Rhodes University, Grahamstown, 6140, South Africa
| | - Setshaba D Khanye
- Department of Chemistry, Faculty of Science, Rhodes University, Grahamstown, 6140, South Africa. .,Centre for Chemico- and Biomedical Research, Rhodes University, Grahamstown, 6140, South Africa. .,Faculty of Pharmacy, Rhodes University, Grahamstown, 6140, South Africa.
| |
Collapse
|
5
|
Forsberg LK, Davis RE, Wimalasena VK, Blagg BSJ. Exploiting polarity and chirality to probe the Hsp90 C-terminus. Bioorg Med Chem 2018; 26:3096-3110. [PMID: 29720349 PMCID: PMC6008240 DOI: 10.1016/j.bmc.2018.04.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2018] [Revised: 04/03/2018] [Accepted: 04/12/2018] [Indexed: 11/18/2022]
Abstract
Inhibition of the Hsp90 C-terminus is an attractive therapeutic approach for the treatment of cancer. Novobiocin, the first Hsp90 C-terminal inhibitor identified, contains a synthetically complex noviose sugar that has limited the generation of structure-activity relationships for this region of the molecule. The work described herein utilizes various ring systems as noviose surrogates to explore the size and nature of the surrounding binding pocket.
Collapse
Affiliation(s)
- Leah K Forsberg
- Department of Chemistry and Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN 46556 USA
| | - Rachel E Davis
- Department of Chemistry and Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN 46556 USA
| | - Virangika K Wimalasena
- Department of Chemistry and Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN 46556 USA
| | - Brian S J Blagg
- Department of Chemistry and Biochemistry, University of Notre Dame, 305 McCourtney Hall, Notre Dame, IN 46556 USA.
| |
Collapse
|
6
|
Abstract
New antibacterials that modulate less explored targets are needed to fight the emerging bacterial resistance. DNA gyrase and topoisomerase IV are attractive targets in this search. These are both type II topoisomerases that can cleave both DNA strands, and can thus alter DNA topology during replication or similar processes. Currently, there are no ATP-competitive inhibitors of these two enzymes on the market, as the only aminocoumarin representative, novobiocin, was withdrawn due to safety concerns. The search for novel ATP-competitive inhibitors is a focus of ongoing industrial and academical research. This review summarizes the recent efforts in the design, synthesis and evaluation of GyrB/ParE inhibitors. The various approaches to achieve improved antibacterial activities are described, with particular reference to Gram-negative bacteria.
Collapse
|
7
|
Forsberg LK, Anyika M, You Z, Emery S, McMullen M, Dobrowsky RT, Blagg BSJ. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects. Eur J Med Chem 2018; 143:1428-1435. [PMID: 29137866 PMCID: PMC5736410 DOI: 10.1016/j.ejmech.2017.10.038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2017] [Revised: 10/09/2017] [Accepted: 10/14/2017] [Indexed: 11/30/2022]
Abstract
Heat shock protein 90 (Hsp90) is a chaperone under investigation for the treatment of cancer and neurodegenerative diseases. Neuroprotective Hsp90 C-terminal inhibitors derived from novobiocin (novologues) include KU-32 and KU-596. These novologues modulate molecular chaperones and result in an induction of Heat Shock Protein 70 (Hsp70). "Noviomimetics" replace the synthetically complex noviose sugar with a simple cyclohexyl moiety to maintain biological efficacy as compared to novologues KU-596 and KU-32. In this study, we further explore the development of noviomimetics and evaluate their efficacy using a luciferase refolding assay, immunoblot analysis, a c-jun assay, and an assay measuring mitochondrial bioenergetics. These new noviomimetics were designed and synthesized and found to induce Hsp70 and improve biological activity. Noviomimetics 39e and 40a were found to induce Hsp70 and exhibit promising effects in cellular assays.
Collapse
Affiliation(s)
- Leah K Forsberg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, United States
| | - Mercy Anyika
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, United States
| | - Zhenyuan You
- Department of Pharmacology and Toxicology Department, The University of Kansas, Lawrence, KS 66045, United States
| | - Sean Emery
- Department of Pharmacology and Toxicology Department, The University of Kansas, Lawrence, KS 66045, United States
| | - Mason McMullen
- Department of Pharmacology and Toxicology Department, The University of Kansas, Lawrence, KS 66045, United States
| | - Rick T Dobrowsky
- Department of Pharmacology and Toxicology Department, The University of Kansas, Lawrence, KS 66045, United States
| | - Brian S J Blagg
- Department of Chemistry and Biochemistry, 305 McCourtney Hall, The University of Notre Dame, Notre Dame, IN 46556, United States.
| |
Collapse
|
8
|
Forsberg LK, Liu W, Holzbeierlein J, Blagg BSJ. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer. Bioorg Med Chem Lett 2017; 27:4514-4519. [PMID: 28844386 DOI: 10.1016/j.bmcl.2017.07.030] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 06/30/2017] [Accepted: 07/10/2017] [Indexed: 01/27/2023]
Abstract
Heat Shock Protein 90 (Hsp90) is a molecular chaperone under clinical investigation for the treatment of neurodegenerative diseases and cancer. Neuroprotective Hsp90 C-terminal inhibitors (novologues) contain a biaryl ring system, and include KU-596, which was modified and investigated for potential anti-cancer activity. Incorporation of a benzamide group onto the biaryl novologues in lieu of the acetamide yielded compounds that manifest anti-cancer activity. Further exploration of the central phenyl ring led to compounds with enhanced anti-proliferative activity. The design, synthesis, and evaluation of these new analogs against breast and prostate cancer cell lines is reported herein, where it was found that 8b and 10 manifest potent anti-proliferative activity and a robust degradation of Hsp90 client-dependent proteins.
Collapse
Affiliation(s)
- Leah K Forsberg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| | - Weiya Liu
- Department of Urology, 3901 Rainbow Boulevard, Stop 3016, The University of Kansas Medical Center, Kansas City, Kansas 66160, United States
| | - Jeffrey Holzbeierlein
- Department of Urology, 3901 Rainbow Boulevard, Stop 3016, The University of Kansas Medical Center, Kansas City, Kansas 66160, United States
| | - Brian S J Blagg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States.
| |
Collapse
|
9
|
Davis RE, Zhang Z, Blagg BSJ. A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library. MEDCHEMCOMM 2017; 8:593-598. [PMID: 28533894 DOI: 10.1039/c6md00377j] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Inhibition of the Hsp90 C-terminus is an attractive therapeutic paradigm for the treatment of cancer, however the developmental space of C-terminal inhibitors is limited. It was hypothesized that the combination of two previously identified scaffolds into a single structure could provide a platform for which to probe the three-dimensional space within the Hsp90 C-terminal binding pocket. The resulting chimeric compounds displayed anti-proliferative activity at low micromolar concentrations and manifested inhibitory activity in an Hsp90-dependent rematuration assay. Initial structure-activity relationships suggest that this new scaffold binds Hsp90 in a conformation different from that of the parent compounds, and consequently, provides a new opportunity to develop more efficacious inhibitors of the Hsp90 C-terminal binding pocket.
Collapse
Affiliation(s)
- Rachel E Davis
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Zheng Zhang
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Brian S J Blagg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| |
Collapse
|
10
|
Abstract
The 90-kDa heat-shock protein (Hsp90) is a molecular chaperone responsible for the stability and function of a wide variety of client proteins that are critical for cell growth and survival. Many of these client proteins are frequently mutated and/or overexpressed in cancer cells and are therefore being actively pursued as individual therapeutic targets. Consequently, Hsp90 inhibition offers a promising strategy for simultaneous degradation of several anticancer targets. Currently, most Hsp90 inhibitors under clinical evaluation act by blocking the binding of ATP to the Hsp90 N-terminal domain and thereby, induce the degradation of many Hsp90-dependent oncoproteins. Although, they have shown some promising initial results, clinical challenges such as induction of the heat-shock response, retinopathy, and gastrointestinal tract toxicity are emerging from human trials, which constantly raise concerns about the future development of these inhibitors. Novobiocin derivatives, which do not bind the chaperone's N-terminal ATPase pocket, have emerged over the past decade as an alternative strategy to inhibit Hsp90, but to date, no derivative has been investigated in the clinical setting. In recent years, a number of natural or synthetic compounds have been identified that modulate Hsp90 function via various mechanisms. These compounds not only offer new chemotypes for the development of future Hsp90 inhibitors but can also serve as chemical probes to unravel the biology of Hsp90. This chapter presents a synopsis of inhibitors that directly, allosterically, or even indirectly alters Hsp90 function, and highlights their proposed mechanisms of action.
Collapse
|
11
|
Hall JA, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BSJ. Novobiocin Analogues That Inhibit the MAPK Pathway. J Med Chem 2016; 59:925-33. [PMID: 26745854 DOI: 10.1021/acs.jmedchem.5b01354] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Heat shock protein 90 (Hsp90) inhibition by modulation of its N- or C-terminal binding site has become an attractive strategy for the development of anticancer chemotherapeutics. The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ∼700 μM. Therefore, investigation of the novobiocin scaffold has led to analogues with improved antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these studies, novobiocin analogues that do not inhibit Hsp90 were identified; however, these analogues demonstrated potent antiproliferative activity. Compound 2, a novobiocin analogue, was identified as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, structural modifications of compound 2 were identified that segregated Hsp90 inhibition from MAPK signaling disruption. These studies indicate that compound 2 represents a novel scaffold for disruption of MAPK pathway signaling and may serve as a useful structure for the generation of new anticancer agents.
Collapse
Affiliation(s)
- Jessica A Hall
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Sahithi Seedarala
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Huiping Zhao
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Gaurav Garg
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Suman Ghosh
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| | - Brian S J Blagg
- Department of Medicinal Chemistry, The University of Kansas , 1251 Wescoe Hall Drive, 4070 Malott Hall, Lawrence, Kansas 66045, United States
| |
Collapse
|
12
|
Terracciano S, Foglia A, Chini MG, Vaccaro MC, Russo A, Piaz FD, Saturnino C, Riccio R, Bifulco G, Bruno I. New dihydropyrimidin-2(1H)-one based Hsp90 C-terminal inhibitors. RSC Adv 2016. [DOI: 10.1039/c6ra17235k] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The inhibition of the C-terminal domain of heat shock protein 90 (Hsp90) is emerging as a novel strategy for cancer therapy, therefore the identification of a new class of C-terminal inhibitors is strongly required.
Collapse
Affiliation(s)
- S. Terracciano
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - A. Foglia
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - M. G. Chini
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - M. C. Vaccaro
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - A. Russo
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - F. Dal Piaz
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
- Department of Medicine and Surgery University of Salerno
| | - C. Saturnino
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - R. Riccio
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - G. Bifulco
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| | - I. Bruno
- Department of Pharmacy
- University of Salerno
- Fisciano
- Italy
| |
Collapse
|
13
|
Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Med Chem 2015; 6:1587-605. [PMID: 25367392 DOI: 10.4155/fmc.14.89] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
Hsp90 is responsible for the conformational maturation of newly synthesized polypeptides (client proteins) and the re-maturation of denatured proteins via the Hsp90 chaperone cycle. Inhibition of the Hsp90 N-terminus has emerged as a clinically relevant strategy for anticancer chemotherapeutics due to the involvement of clients in a variety of oncogenic pathways. Several immunophilins, co-chaperones and partner proteins are also necessary for Hsp90 chaperoning activity. Alternative strategies to inhibit Hsp90 function include disruption of the C-terminal dimerization domain and the Hsp90 heteroprotein complex. C-terminal inhibitors and Hsp90 co-chaperone disruptors prevent cancer cell proliferation similar to N-terminal inhibitors and destabilize client proteins without induction of heat shock proteins. Herein, current Hsp90 inhibitors, the chaperone cycle, and regulation of this cycle will be discussed.
Collapse
|
14
|
Garg G, Zhao H, Blagg BSJ. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors. ACS Med Chem Lett 2015; 6:204-9. [PMID: 25699150 DOI: 10.1021/ml5004475] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Accepted: 12/12/2014] [Indexed: 12/22/2022] Open
Abstract
Hsp90 C-terminal inhibitors represent a novel and alternative chemotherapeutic approach for the treatment of cancer. Novobiocin was the first natural product identified as an Hsp90 C-terminal inhibitor; however, it manifests poor antiproliferative activity. In contrast to N-terminal inhibitors, novobiocin does not induce the pro-survival heat shock response. Structural investigations on novobiocin have elucidated some structure-activity relationships and several promising compounds. On the basis of structure-activity relationships and computational studies, a library of ring-constrained novobiocin analogues was designed, synthesized, and evaluated in antiproliferative assays. Results obtained from these studies provide insights into the Hsp90 C-terminal binding site, and new analogues that were developed manifest low micromolar to mid-nanomolar antiproliferative activity resulting from Hsp90 inhibition.
Collapse
Affiliation(s)
- Gaurav Garg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7563, United States
| | - Huiping Zhao
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7563, United States
| | - Brian S. J. Blagg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7563, United States
| |
Collapse
|
15
|
Zhao H, Garg G, Zhao J, Moroni E, Girgis A, Franco LS, Singh S, Colombo G, Blagg BSJ. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. Eur J Med Chem 2014; 89:442-66. [PMID: 25462258 DOI: 10.1016/j.ejmech.2014.10.034] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 08/13/2014] [Accepted: 10/12/2014] [Indexed: 11/18/2022]
Abstract
Modulation of Hsp90 C-terminal function represents a promising therapeutic approach for the treatment of cancer and neurodegenerative diseases. Current drug discovery efforts toward Hsp90 C-terminal inhibition focus on novobiocin, an antibiotic that was transformed into an Hsp90 inhibitor. Based on structural information obtained during the development of novobiocin derivatives and molecular docking studies, scaffolds containing a biphenyl moiety in lieu of the coumarin ring present in novobiocin were identified as new Hsp90 C-terminal inhibitors. Structure-activity relationship studies produced new derivatives that inhibit the proliferation of breast cancer cell lines at nanomolar concentrations, which corresponded directly with Hsp90 inhibition.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Gaurav Garg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Jinbo Zhao
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Elisabetta Moroni
- Istituto di chimica del riconoscimento molecolare, CNR, Via Mario Bianco 9, 20131 Milano, Italy
| | - Antwan Girgis
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Lucas S Franco
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Swapnil Singh
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | - Giorgio Colombo
- Istituto di chimica del riconoscimento molecolare, CNR, Via Mario Bianco 9, 20131 Milano, Italy
| | - Brian S J Blagg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA.
| |
Collapse
|
16
|
Zhao H, Anyika M, Girgis A, Blagg BSJ. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. Bioorg Med Chem Lett 2014; 24:3633-7. [PMID: 24953820 PMCID: PMC4096108 DOI: 10.1016/j.bmcl.2014.05.020] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2014] [Revised: 04/30/2014] [Accepted: 05/05/2014] [Indexed: 01/03/2023]
Abstract
Hsp90 represents a promising target for the development of both anti-cancer and neuroprotective agents. Structure-activity relationship studies on novobiocin and novobiocin analogues, led to the development of KU-32 and recently, KU-596, as lead compounds for the potential treatment of neurodegenerative diseases. Similar to KU-32, we have demonstrated that upon replacement of the acetamide side chain present in KU-32 with a benzamide, this neuroprotective agent was transformed into a scaffold that manifests anti-proliferative activity. To assess structure-activity relationships for this new scaffold, a library of benzamide-containing novologues was prepared and evaluated against two breast cancer cell lines. Compound 14a manifested the most potent anti-proliferative activity from these studies and induced Hsp90-dependent client protein degradation in a concentration-dependent manner.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KS 66045-7563, United States
| | - Mercy Anyika
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KS 66045-7563, United States
| | - Antwan Girgis
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KS 66045-7563, United States
| | - Brian S J Blagg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, KS 66045-7563, United States.
| |
Collapse
|
17
|
Moroni E, Zhao H, Blagg BSJ, Colombo G. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities. J Chem Inf Model 2014; 54:195-208. [PMID: 24397468 DOI: 10.1021/ci4005767] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
The interaction that occurs between molecules is a dynamic process that impacts both structural and conformational properties of the ligand and the ligand binding site. Herein, we investigate the dynamic cross-talk between a protein and the ligand as a source for new opportunities in ligand design. Analysis of the formation/disappearance of protein pockets produced in response to a first-generation inhibitor assisted in the identification of functional groups that could be introduced onto scaffolds to facilitate optimal binding, which allowed for increased binding with previously uncharacterized regions. MD simulations were used to elucidate primary changes that occur in the Hsp90 C-terminal binding pocket in the presence of first-generation ligands. This data was then used to design ligands that adapt to these receptor conformations, which provides access to an energy landscape that is not visible in a static model. The newly synthesized compounds demonstrated antiproliferative activity at ∼150 nM concentration. The method identified herein may be used to design chemical probes that provide additional information on structural variations of Hsp90 C-terminal binding site.
Collapse
Affiliation(s)
- Elisabetta Moroni
- Istituto di chimica del riconoscimento molecolare, CNR. Via Mario Bianco 9, 20131 Milano, Italy
| | | | | | | |
Collapse
|
18
|
Zhao H, Moroni E, Colombo G, Blagg BSJ. Identification of a new scaffold for hsp90 C-terminal inhibition. ACS Med Chem Lett 2014; 5:84-8. [PMID: 24900777 DOI: 10.1021/ml400404s] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2013] [Accepted: 11/10/2013] [Indexed: 01/07/2023] Open
Abstract
Inhibition of Hsp90 C-terminal function is an advantageous therapeutic paradigm for the treatment of cancer. Currently, the majority of Hsp90 C-terminal inhibitors are derived from novobiocin, a natural product traditionally used as an antibiotic. Assisted by molecular docking studies, a scaffold containing a biphenyl moiety in lieu of the coumarin ring system found in novobiocin was identified for development of new Hsp90 C-terminal inhibitors. Initial structure-activity studies led to derivatives that manifest good antiproliferative activity against two breast cancer cell lines through Hsp90 inhibition. This platform serves as a scaffold upon which new Hsp90 C-terminal inhibitors can be readily assembled for further investigation.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott
4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| | - Elisabetta Moroni
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via
Mario Bianco 9, 20131 Milano, Italy
| | - Giorgio Colombo
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via
Mario Bianco 9, 20131 Milano, Italy
| | - Brian S. J. Blagg
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott
4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| |
Collapse
|
19
|
Sheng J, Fan C, Wu J. Generation of 4-substituted coumarins via C–H bond activation under palladium bromide–copper(I) bromide cooperative catalysis. Tetrahedron 2013. [DOI: 10.1016/j.tet.2013.10.043] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Zhao H, Blagg BSJ. Novobiocin analogues with second-generation noviose surrogates. Bioorg Med Chem Lett 2012; 23:552-7. [PMID: 23234644 DOI: 10.1016/j.bmcl.2012.11.022] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2012] [Revised: 11/01/2012] [Accepted: 11/07/2012] [Indexed: 11/20/2022]
Abstract
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90 C-terminal inhibitor ever identified and recent structure-activity relationship studies on the noviose sugar identified several commercially available amines as suitable surrogates. In an effort to further understand this region of the molecule, analogues containing various N'-amino substituents were prepared and evaluated against two breast cancer cell lines for determination of their efficacy. Compound 37j manifested the most potent anti-proliferative activity from these studies and induced Hsp90-dependent client protein degradation at mid nano-molar concentrations.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | | |
Collapse
|
21
|
Zhao H, Yan B, Peterson LB, Blagg BSJ. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. ACS Med Chem Lett 2012; 3:327-331. [PMID: 23316269 DOI: 10.1021/ml300018e] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
The potential therapeutic benefits associated with Hsp90 modulation for the treatment of cancer and neurodegenerative diseases highlight the importance of identifying novel Hsp90 scaffolds. KU-398, a novobiocin analogue, and silybin were recently identified as new Hsp90 inhibitors. Consequently, a library of 3-arylcoumarin derivatives that incorporated the structural features of KU-398 and silybin was designed, synthesized and evaluated against two breast cancer cell lines. Western blot analysis confirmed that the resulting 3-arylcoumarin hybrids target the Hsp90 protein folding machinery.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal
Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| | - Bin Yan
- Department of Medicinal
Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| | - Laura B. Peterson
- Department of Medicinal
Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| | - Brian S. J. Blagg
- Department of Medicinal
Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, Kansas 66045-7563, United States
| |
Collapse
|
22
|
Zhao H, Moroni E, Yan B, Colombo G, Blagg BSJ. 3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. ACS Med Chem Lett 2012; 4:57-62. [PMID: 23606927 DOI: 10.1021/ml300275g] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Hsp90 is an attractive therapeutic target for the treatment of cancer. Extensive structural modifications to novobiocin, the first Hsp90 C-terminal inhibitor discovered, have produced a library of novobiocin analogues and revealed some structure-activity relationships. Based upon the most potent novobiocin analogues generated from prior studies, a three-dimensional quantitative structure-activity (3D-QSAR) model was built. In addition, a new set of novobiocin analogues containing various structural features supported by the 3D-QSAR model were synthesized and evaluated against two breast cancer cell lines. Several new inhibitors produced anti-proliferative activity at mid nano-molar concentrations, which results through Hsp90 inhibition.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott
4070, Lawrence, Kansas 66045-7563, United States
| | - Elisabetta Moroni
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via Mario Bianco
9, 20131 Milano, Italy
| | - Bin Yan
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott
4070, Lawrence, Kansas 66045-7563, United States
| | - Giorgio Colombo
- Istituto di Chimica del Riconoscimento Molecolare, CNR, Via Mario Bianco
9, 20131 Milano, Italy
| | - Brian S. J. Blagg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott
4070, Lawrence, Kansas 66045-7563, United States
| |
Collapse
|
23
|
Kusuma BR, Duerfeldt AS, Blagg BSJ. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorg Med Chem Lett 2011; 21:7170-4. [PMID: 22014546 PMCID: PMC3242434 DOI: 10.1016/j.bmcl.2011.09.073] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2011] [Revised: 09/16/2011] [Accepted: 09/19/2011] [Indexed: 01/01/2023]
Abstract
Novobiocin analogs lacking labile glycosidic ether have been designed, synthesized and evaluated for Hsp90 inhibitory activity. Replacement of the synthetically complex noviose sugar with simple aromatic side chains produced analogs that maintain moderate cytotoxic activity against MCF7 and SkBR3 breast cancer cell-lines. Rationale for the preparation of des-noviose novobiocin analogs in addition to their synthesis and biological evaluation are presented herein.
Collapse
Affiliation(s)
- Bhaskar Reddy Kusuma
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott Hall 4070, Lawrence, Kansas 66045-7563
| | - Adam S. Duerfeldt
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott Hall 4070, Lawrence, Kansas 66045-7563
| | - Brian S. J Blagg
- Department of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Malott Hall 4070, Lawrence, Kansas 66045-7563
| |
Collapse
|
24
|
Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BSJ. Targeting the heat shock protein 90 dimer with dimeric inhibitors. J Med Chem 2011; 54:6234-53. [PMID: 21861487 DOI: 10.1021/jm200553w] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The design, synthesis, and biological evaluation of conformationally constrained coumermycin A1 analogues are reported. Compounds were evaluated against both breast cancer (SKBr3 and MCF7) and prostate cancer (PC3 mm2, A549, and HT29) cell lines. Non-noviosylated coumermycin A1 analogues that manifest potent antiproliferative activity resulting from Hsp90 inhibition are provided, wherein replacement of the stereochemically complex noviose sugar with readily available piperidine rings resulted in ∼100 fold increase in antiproliferative activities as compared to coumermycin A1, producing small molecule Hsp90 inhibitors that exhibit nanomolar activities.
Collapse
Affiliation(s)
- Bhaskar Reddy Kusuma
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045-7563, USA
| | | | | | | | | | | |
Collapse
|
25
|
Zhao H, Donnelly AC, Kusuma BR, Brandt GEL, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BSJ. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. J Med Chem 2011; 54:3839-53. [PMID: 21553822 DOI: 10.1021/jm200148p] [Citation(s) in RCA: 141] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Development of the DNA gyrase inhibitor, novobiocin, into a selective Hsp90 inhibitor was accomplished through structural modifications to the amide side chain, coumarin ring, and sugar moiety. These species exhibit ∼700-fold improved anti-proliferative activity versus the natural product as evaluated by cellular efficacies against breast, colon, prostate, lung, and other cancer cell lines. Utilization of structure-activity relationships established for three novobiocin synthons produced optimized scaffolds, which manifest midnanomolar activity against a panel of cancer cell lines and serve as lead compounds that manifest their activities through Hsp90 inhibition.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, The University of Kansas, Lawrence, KS 66045-7563, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Meng T, Zou Y, Khorev O, Jin Y, Zhou H, Zhang Y, Hu D, Ma L, Wang X, Shen J. Simple and Efficient Copper(I)-Catalyzed Access to Three Versatile Aminocoumarin-Based Scaffolds using Isocyanoacetate. Adv Synth Catal 2011. [DOI: 10.1002/adsc.201000895] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Zhao H, Brandt GE, Galam L, Matts RL, Blagg BSJ. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorg Med Chem Lett 2010; 21:2659-64. [PMID: 21273068 DOI: 10.1016/j.bmcl.2010.12.088] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2010] [Revised: 12/14/2010] [Accepted: 12/16/2010] [Indexed: 11/20/2022]
Abstract
Through Hsp90-dependent firefly luciferase refolding and Hsp90-dependent heme-regulated eIF2α kinase (HRI) activation assays, silybin was identified as a novel Hsp90 inhibitor. Subsequently, a library of silybin analogues was designed, synthesized and evaluated. Initial SAR studies identified the essential, non-essential and detrimental functionalities on silybin that contribute to Hsp90 inhibition.
Collapse
Affiliation(s)
- Huiping Zhao
- Department of Medicinal Chemistry, 1251 Wescoe Hall Drive, Malott 4070, The University of Kansas, Lawrence, KS 66045-7563, USA
| | | | | | | | | |
Collapse
|
28
|
Vaughan CK, Neckers L, Piper PW. Understanding of the Hsp90 molecular chaperone reaches new heights. Nat Struct Mol Biol 2010; 17:1400-4. [PMID: 21127511 PMCID: PMC7560985 DOI: 10.1038/nsmb1210-1400] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Heat shock protein 90 (Hsp90) was the focus of a recent meeting in the Swiss Alps, where the Hsp90 community met to discuss the operation and functions of this ubiquitous and essential molecular chaperone.
Collapse
Affiliation(s)
- Cara K Vaughan
- Cara K. Vaughan is at the Institute of Structural Molecular Biology, Birkbeck College, London, UK
| | | | | |
Collapse
|